Marcus Keep, M.D.
Marcus Keep, M.D. is the founder and CEO of Maas Biolab.
Dr. Keep is a board certified neurosurgeon in both the United States and Canada. He is a full time Trauma Neurosurgeon at Sanford Medical Center in Fargo, which is the only Level 1 (the highest level) Trauma Center for all of North Dakota. Dr. Keep is a member of the joint American Association and Congress of Neurological Surgeons-Section on NeuroTrauma & Critical Care since 2003.
His neurosurgery residency training was at the Montreal Neurological Institute, McGill University, Canada. Dr. Keep received his MD from the Medical University of South Carolina in Charleston. His bachelor of science in Chemistry was earned at University of South Carolina. Marcus’s bachelor of arts was in Religion from Dartmouth College, Hanover, New Hampshire.
Dr. Keep had neuroscience research fellowships at INSERM U106 with Dr. Constantino Sotelo, Pitié-Salpêtrière Hospital, Paris, France, and the Section of Restorative Neurology with Dr. Olle Lindvall, Lund University Hospital, Sweden. He performed ALS research with Jenny Karlsson, PhD, at the University of Hawaii, Honolulu, and Albuquerque, New Mexico. Drs. Keep and Karlsson’s basic neuroscience research revealed that intrathecal cyclosporin treatments doubled the post-diagnosis lifespan of ALS mice, slowed progression of the disease, and preserved motor neurons. Marcus designed our intrathecal cyclosporin formula Mitogard® to treat ALS.
Dr. Keep recruited Michael Vickers after his graduation from the Anderson School of Management at the University of New Mexico to join Maas Biolab, with the support of TVC, the nonprofit arm of Lockheed Martin. Jenny Karlsson, PhD was recruited from the laboratory of Patrik Brundin, MD, PhD, Section of Neuronal Survival, Wallenburg Neuroscience Center, Lund University, for postdoctoral studies in ALS. She joined Maas Biolab as Director of PreClinical Development. Together Michael Vickers, Jenny Karlsson, and Marcus Keep are the core team of Maas Biolab working to bring Mitogard® intrathecal cyclosporin to people with ALS.
Dr. Keep has additional external experience in the Pharma field. He was on the Board of Directors for 18 years at public NeuroVive Pharmaceutical until April 2018. Dr. Keep wrote their first cyclosporin patents, advocated for their developing treatments for traumatic brain injury (TBI), created the trademark name NeuroSTAT® for their TBI drug, urged them to not abandon promising drugs that might only give reasonable returns, and was instrumental in getting this Swedish Nasdaq stock (NVP.ST) traded by American and international investors through a listing on New York City’s Over The Counter OTC Market (ticker NEVPF).
Marcus Keep is an advisor to Xintela AB, a public Swedish biopharma (ticker XINT.ST), helping them design their Antibody-Drug Conjugate (ADC) treatment for glioblastoma multiformi (GBM), the most lethal adult brain cancer.
Dr. Keep studied in 2017 with the Bob Giordano Group at Network 1 Financial, the art of fundraising for small private and public health science companies through investment banks, and family offices.